• Subscribe
  • Register for free Content
  • Cart
  • Login
  • Browse by Topic
    • 13 Reasons Why
    • Abstinence
    • Acamprosate
    • Addiction
    • Addiction Treatment
    • Addyi
    • Adhansia XR
    • ADHD
    • Adherence
    • adolescents
    • Adult ADHD
    • Adverse Childhood Experiences (ACES)
    • Affordable Care Act (ACA)
    • Agitation
    • air pollution
    • Akathisia
    • Alcohol
    • Alcohol Use
    • Alcohol use disorder
    • Alcoholism
    • Alpha Agonists
    • Alternative treatments
    • Amantadine
    • amphetamine
    • Amphetamines
    • Anorexia Nervosa
    • Antidepressant Augmentation
    • Antidepressants
    • Antipsychotic
    • Antipsychotics
    • Anxiety
    • Anxiety Disorder
    • APA CE Post-Test
    • Aripiprazole
    • ArModafinil
    • Asenapine
    • Assessment
    • asthma
    • atamoxetine
    • attention
    • Attention Deficit Hyperactivity Disorder
    • Atypical Antipsychotics
    • Austedo
    • Autism
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder
    • Autism Spectrum Disorder autism spectrum disorder
    • Behavior therapy
    • Behavioral addiction
    • Behavioral therapy
    • Behavioral treatment
    • Belsomra
    • Benzodiazepines
    • Beta-blockers
    • Billing
    • Bipolar Depression
    • Bipolar Disorder
    • Bipolar II
    • Board Certification
    • Borderline Personality Disorder
    • BPD
    • Brain Devices
    • Brief psychotherapy
    • Brief Strategic Family Therapy (BFST)
    • Bullying
    • Buprenorphine
    • Bupropion
    • Buspirone
    • C-Reactive Protein
    • Caffeine
    • CAM Treatments
    • Cannabidiol
    • Cannabis
    • Caplyta
    • Carbamazepine
    • Cardiovascular
    • Cariprazine
    • Chantix
    • Child and adolescent
    • Child Psychiatry
    • Child Psychiatry
    • children
    • Chokroverty
    • Citalopram
    • Clinical practice
    • Clozapine
    • CME Post-Test
    • Co-occurring disorders
    • Cocaine
    • Cognition
    • Cognitive Behavioral Therapy
    • Cognitive Decline
    • cognitive impact
    • Cognitive Rehabilitation Therapy (CRT)
    • Collaborative care
    • community trauma
    • Comorbidity
    • Complementary treatments
    • Complimentary treatments
    • Computer addiction
    • Computers in Psychiatric Practice
    • Conduct Disorder
    • Confidentiality
    • Connect
    • Connection
    • Connections
    • Contagion
    • Coronavirus
    • Cosmetic pharmacology
    • COVID-19
    • COVID19
    • Creativity
    • Crime
    • Criminal behavior
    • Crisis intervention
    • Crocus Sativus
    • CRP
    • Cultural Competence
    • Culture
    • Cymbalta
    • Dayvigo
    • Delusional Disorder
    • Dementia
    • Deplin
    • Deprescribing
    • Depression
    • Depressive Disorder
    • Deutetrabenazine
    • Diagnosis
    • Diagnostic Testing
    • Disaster
    • Disparities
    • Diversity
    • Dopamine
    • DSM
    • Dual diagnosis
    • Duloxetine
    • Dyslexia
    • Dysregulation
    • E-Cigarettes
    • Eating Disorders
    • eCigarettes
    • ECT
    • Effexor
    • efficacy
    • electronic use
    • emergent suicidality
    • Emotional dysregulation
    • End of Life Care
    • Engagement
    • Escitalopram
    • Esketamine
    • eTNS
    • Exercise
    • Existing marijuana
    • expressed emotion
    • extended-release
    • Falls
    • Family Separation
    • FDA Warnings
    • Female hypoactive sexual desire disorder
    • Female Issues in Psychiatry
    • Fluoxetine
    • Folate
    • Folic Acid
    • Free Articles
    • gabapentin
    • GAD
    • Gender
    • Gender & Sexuality
    • Gender Diverse
    • Gender Dysphoria
    • Gender Identity
    • Generalized Anxiety Disorder
    • Generics
    • GeneSight
    • Genetic Testing
    • Genetics and Psychiatry
    • Geriatric Psychiatry
    • Ginkgo
    • Guanfacine
    • Hair loss
    • Harm reduction
    • Head Trauma
    • Health Apps
    • Heart health
    • Heart rate
    • Hepatitis
    • Heroin
    • HIPAA
    • Histamine
    • HIV
    • Hormone Replacement Therapy
    • Hypnotics
    • Hypomania
    • Incarceration
    • Inflammation
    • Ingrezza
    • Inpatient Psychiatry
    • inquiry
    • Insomnia
    • Insurance
    • Internet
    • Interpreter
    • Intervention
    • Irritability
    • Keppra
    • Ketamine
    • l-methylfolate
    • Laboratory Testing in Psychiatry
    • Lamictal
    • Lamotrigine
    • Language
    • Lavender
    • Learning & Developmental Disabilities
    • Legal issues
    • Lemborexant
    • Levetiracetam
    • LGBT
    • LGBTQ+
    • Life coaching
    • Life expectancy
    • Light and Dark Therapy
    • Light therapy
    • Lightbox
    • Literacy
    • Lithium
    • Longevity
    • Low libido
    • Lumateperone
    • Lurasidone
    • Lyrica
    • Management
    • Mania
    • Mania on Antidepressants
    • MAOIs
    • Marijuana
    • Media
    • Medical Comorbidities
    • Medication
    • Medication adherence
    • Melatonin
    • Meta-analysis
    • Metabolic syndrome
    • Metformin
    • Methadone
    • methylfolate
    • methylphenidate
    • Micronutrients
    • Mind-Gut Connection
    • Mindfulness
    • Minority
    • Mirtazapine
    • Mixed Features
    • Modafinil
    • Mood Stabilizers
    • Mortality
    • Motivational Interviewing
    • Naloxone
    • Naltrexone
    • Narcolepsy
    • Natural Medications
    • natural treatments
    • Negative Symptoms
    • Netflix
    • Neurology
    • Neuroscience in Psychiatry
    • Neurotoxicity
    • New York
    • News of Note
    • Nightmares
    • Norepinephrine
    • Nortriptyline
    • Novel Medications
    • Nuedexta
    • Nuplazid
    • Nutrition
    • Nuvigil
    • Obesity
    • observational study
    • OCD
    • olanzapine
    • online therapy
    • Opioid epidemic
    • Opioid Use Disorder
    • Opioids
    • Oral Contraceptives
    • Orexin
    • Orthostasis
    • Outpatient
    • Overdose
    • Oxcarbazepine
    • Pain
    • pandemic
    • Panic Disorder
    • Parenting Strategies
    • Parkinson’s
    • Parkinson’s Disease
    • Paroxetine
    • Particulate matter
    • Patch
    • Patient relationship
    • pediatric
    • Perseveration
    • Perseverative Behavior
    • Personality Disorders
    • Pharmaceutical Industry
    • Pharmacology
    • Pharmacology Tips
    • Pharmacy
    • phonemic awareness
    • Phonics
    • Physician assisted suicide
    • PICOT
    • Pimozide
    • Pitolisant
    • Podcast
    • polypharmacy
    • Postpartum Depression
    • Potency
    • Practice Tools and Tips
    • Practice Tools and Tips
    • Pramipexole
    • Prazosin
    • Pregabalin
    • Pregnancy
    • prescribing patterns
    • Prescription costs
    • Prevention
    • Primary care
    • Prison
    • Prodrome
    • Prolonged exposure
    • Promotoras
    • Pronouns
    • Provigil
    • Prozac
    • pseudobulbar affect
    • Psychiatric interviewing
    • Psychological First Aide
    • Psychopharm Myths
    • Psychopharmacology
    • Psychopharmacology Tips
    • Psychosis
    • Psychotherapy
    • Psychotherapy
    • Psychotic Depression
    • Psychotropic medication
    • PTSD
    • Public health
    • Quality of care
    • quality of life
    • Quetiapine
    • Randomized controlled trial
    • rapid naming
    • Reading
    • Reading disorder
    • Reading Disorders
    • Reading remediation
    • Red Cross
    • Registered Articles
    • Relationships
    • Remediation
    • Repetitive Behavior
    • Repetitive behaviors
    • Research
    • Research Update
    • Research Updates
    • retention
    • Retirement
    • Risk
    • Risk Management
    • Risperidone
    • Ritalin
    • rTMS
    • safety
    • Saffron
    • Saphris
    • Schizophrenia
    • School Refusal
    • Seasonal Affective Disorder
    • Secuado
    • Self-injury
    • Self-Regulation
    • Serotonin Specific Reuptake Inhibitors (SSRIs)
    • Sertraline
    • Sex Therapy
    • Sexual Dysfunction
    • Sexual Side Effects
    • Side Effects
    • Silexan
    • Skype
    • Sleep
    • Sleep Apnea
    • Sleep Disorders
    • Smoking Cessation
    • Smoking Cessation Agents
    • smoking cessations
    • Social Anxiety Disorder
    • social cohesion
    • Special populations
    • SSRIs
    • Stereotypical Behavior
    • steroids
    • Stigma
    • stimulant
    • Stimulants
    • structured literacy
    • Suboxone
    • Substance Abuse
    • Substance Abuse
    • Substance Use
    • Substance Use Disorder
    • Substance use disorders
    • Suicidality
    • Suicide
    • Suvorexant
    • Symptom Assessment
    • Symptom Management
    • Systematic review
    • Tags
    • Tardive dyskinesia
    • Technology
    • Teen
    • teens
    • Telehealth
    • Telemed
    • Telemedicine
    • Telepsychiatry
    • test cme quiz
    • TGD
    • Therapy during medication appointment
    • Therapy with Med Management
    • TMS
    • Tobacco
    • tobacco research
    • Tobacco use disorder
    • Toxic Stress
    • Transcranial Magnetic Stimulation
    • Transdermal
    • Transgender
    • Translator
    • Trauma
    • Trauma Informed Care
    • Traumatic Brain Injury (TBI)
    • Trazodone
    • treatment
    • treatment pediatric
    • Treatment planning
    • Treatment-Resistant Depression
    • Trigeminal Nerve Stimulation
    • Trintellix
    • Understanding Psychiatric Research
    • Valbenazine
    • Vaping
    • Varenicline
    • Venlafaxine
    • videogaming addiction
    • Violence
    • Vitamin B6
    • Vitamin D
    • Vitamin E
    • VMAT2 Inhibitors
    • Vortioxetine
    • Vyleesi
    • Wakix
    • Weed
    • Weight gain
    • Weight Loss Medications
    • Wellbutrin
    • Wilderness Therapy Programs
    • Withdrawal
    • Women's Issues in Psychiatry
    • Women’s Issues in Psychiatry
    • Working With Families
    • Youth
  • HOME
  • STORE
  • CME CENTER
  • Blog
  • Podcast
  • NEWSLETTERS
    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
  • Archive
  • Archive
  • Archive
  • The Carlat Psychiatry Report
  • Anxiety (May)
  • Benzodiazepines for Anxiety: Where They Fit In

Benzodiazepines for Anxiety: Where They Fit In

The Carlat Psychiatry Report, Volume 16, Number 5, April 2018
https://www.thecarlatreport.com/newsletter-issue/tcprv16n5/

From The Carlat Psychiatry Report, April 2018, Anxiety

Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Topics: Anxiety | Anxiety Disorder | Free Articles | Registered Articles

Print Friendly, PDF & Email

Michael Posternak, MD.

Psychiatrist in private practice, Boston, MA

Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Benzodiazepines (BZDs) are widely used, rarely studied, and much maligned. So where exactly do they fit in today’s medication arsenal for treating anxiety? In this article, I will discuss when BZDs are appropriate and when they are not, and how to choose among the various BZDs.

But before doing so, let’s first address the elephant that always seems to be lurking in the BZD room: their addictive potential.

“I’ve heard that benzodiazepines are highly addictive; are they?” It’s one of the most common concerns patients share with me. While BZDs can be abused, the research shows that the vast majority of those abusing BZDs are also concurrently abusing other substances (Busto UE at al, J Clin Psychopharmacol 1996;16(1):51–57).

A task force assembled by the American Psychiatric Association that looked at BZD abuse concluded that the number of patients actually abusing BZDs is “relatively small”—perhaps less than 1% (Rifkin A et al, Am J Psychiatry 1989;146(10):1331–1332). Even most former substance abusers do not appear to be at greatest risk for abusing BZDs (Posternak MA and Mueller TI, Am J Addict 2001;10(1):48–68).

Opioid use, however, presents a clear exception to this rule: Opioid users often report utilizing BZDs ­specifically to enhance the opioid “high,” and the co-use of opioids with BZDs has negative consequences for general health, treatment outcome, and overdose lethality (Jones JD et al, Drug Alcohol Depend 2012;125(1-2):8–18). BZDs are therefore contraindicated in current opioid users.

What about the fear that BZDs may trigger relapse of other substance use disorders, such as to alcohol? Most research suggests that just the opposite is true. If anything, BZD use may lead to lower rates of substance relapse (Caplan RD et al, Soc Sci Med 1985;21(8):887–898).

Similarly, while it is true that long-term BZD use can induce physiological dependency and withdrawal symptoms, this is not the same as having a substance use disorder. If it were, then paroxetine, venlafaxine, and lithium, among others, would also have to be considered “addictive” medications. Rather, it just means that BZDs need to be tapered off slowly—as is done with many antidepressants and mood stabilizers. For patients who remain hesitant to even try using BZDs, I suggest a limited supply (eg, 10–25 pills per month). I then reassure them, “You can’t get physically dependent on a medication you don’t take every day.”

How to choose among the BZDs
BZDs all share the same mechanism of action: increasing GABA transmission, which has direct anti-anxiety effects, plus sedative effects at higher doses. The main distinction between BZDs is how quickly they work and how long they last. Typically, the faster they kick in, the sooner they wear off; the slower they kick in, the longer they last. The one exception to this rule is diazepam. Because it is lipophilic—meaning it enters fat cells and is slowly released from these cells over time—diazepam works quickly but lasts a long time (this dual feature makes diazepam particularly well suited for treating insomnia).

While there are over a dozen BZDs on the market, you probably will only ever need to use 5 or 6 of the most commonly prescribed ones. These can be ranked from fast-acting to longest-acting in the following order: alprazolam -> lorazepam -> clonazepam -> alprazolam XR.

Diazepam does not fit neatly into this chart because, as stated, it works quickly and lasts a long time. One other BZD that can come in handy is clonazepam wafers. These are taken sublingually and work even faster than alprazolam (alternatively, some clinicians have found that patients can bite traditional BZDs and chew them under their tongue, which allows them to be absorbed more quickly). We will see how these pharmacokinetic differences may affect our choice of BZD depending on the purpose. (For a table of frequently prescribed BZDs and their characteristics, see page 3.)

Prescribing BZDs for anxiety:

The DSM matters!
Anxiety is a fear-driven state of internal distress. It is often useful to distinguish between mental anxiety (worries, ruminations, obsessions) and physical anxiety (chest pain, palpitations, sweating, etc). While patients typically know when they are “anxious,” they don’t necessarily distinguish between various anxiety states. The DSM-5 lists 6 distinct anxiety disorders, and I would argue that the role of BZDs in each specific anxiety disorder is distinct.

As a result, it is not sufficient to simply diagnose your patient as having “anxiety.” Since each disorder may require a different treatment plan, you should always evaluate which anxiety disorders a patient suffers from. In fact, most anxious patients suffer from multiple anxiety disorders. For example, a recent large-scale epidemiological study found that about half of all patients with generalized anxiety disorder have at least 1 other anxiety disorder (Ruscio AM, JAMA Psychiatry 2017;74(5):465–475).

BZDs for each specific anxiety disorder

Panic disorder
Panic attacks are called “panic” for good reason: The sudden onset of overwhelming dread—accompanied by physical symptoms, such as chest pain, palpitations, and shortness of breath—is one of the most crippling experiences patients face. In these situations, patients typically want immediate relief, so the best choice is usually alprazolam (or clonazepam wafers). For many patients, just knowing they have an antidote in their back pocket goes a long way toward staving off future panic attacks. When panic attacks are infrequent, this will typically suffice. But when panic attacks occur more commonly, daily prophylactic medications may be necessary. In these cases, SSRIs may be part of a better long-term solution.

But SSRIs don’t always work, and many patients either do not tolerate them or would prefer to avoid taking daily medications. If so, cognitive behavioral therapy (CBT) should be offered as an alternative. CBT teaches patients how to overcome panic attacks on their own, and therefore—in contrast to medications—can provide an actual cure for panic disorder.

There is one crucial point to keep in mind: CBT only works when patients experience their anxiety. When BZDs help, they actually may prevent the long-term benefits that CBT can offer (Marks IM et al, Br J Psychiatry 1993;162:776–787). Why? Because exposure—both to the feared situation and to the anxiety itself—is the mechanism by which CBT works. If BZDs eliminate patients’ physiological anxiety, then they will not have the opportunity to gain mastery over their anxiety symptoms.

What about patients who want immediate relief from their panic attacks, but also want to engage in CBT so they can get off medications altogether? In these instances, you can offer BZDs now for immediate relief, and in coordination with their CBT therapist, you can plan to wean them off their BZDs. In these instances, the tapering off BZDs becomes the exposure exercise itself: The expectation is that the anxiety may increase during the tapering process. Thus, patients are now choosing to face their anxiety.

Generalized anxiety disorder
Patients with generalized anxiety disorder (GAD) are chronic worriers. Worrying has its advantages, but it can also be extremely taxing. Although SSRIs/SNRIs and buspirone are FDA-approved options for GAD, CBT teaches people how to worry less. Because GAD patients have chronic, daily anxiety, BZDs are not an ideal choice since they would only offer sustained relief when taken daily over an extended period of time. BZDs then are best reserved as a last-resort option for the most severe GAD patients, who have failed on CBT, SSRIs, and buspirone. In these cases, and given its long half-life, alprazolam XR is usually the best option. It can sometimes be dosed once a day, but more often requires BID dosing (typical range 0.5 mg–2 mg QD or BID).

Table: Characteristics of Commonly Used Benzodiazepines

Table: Characteristics of Commonly Used Benzodiazepines

(Click to view as full-size PDF.)

Obsessive-compulsive disorder
Patients with OCD have intrusive, distressing thoughts (obsessions) often associated with compensatory behaviors (compulsions). Despite the high level of anxiety OCD patients can display, BZDs have never been shown to be useful for OCD’s core symptoms, and therefore have no role in treating this disorder.

Social anxiety disorder
Social anxiety disorder (SAD) can range from mild to debilitating, and it can be circumscribed (only manifesting in certain scenarios, such as public speaking) or generalized. Since it potentially limits social functioning and career advancement, more than perhaps any other anxiety disorder, SAD can affect one’s quality of life. Once again, unless the social situation is circumscribed or predictable, CBT and SSRIs will typically be your first-line options. For example, a patient who gets very anxious in meetings may benefit from a BZD 30–60 minutes before that meeting. The same would apply for someone who gets anxious before going on a date (although the patient would need to careful about drinking alcohol) or giving a speech. If physiological symptoms are prominent (particularly palpitations), beta blockers, such as propranolol 20 mg–40 mg, may be a better choice; they are non-sedating and do not impair cognition.

Specific phobias
You may not typically screen for specific phobias. After all, how many patients come in looking for help with their fear of snakes or spiders? But there are two phobias that can be quite debilitating: flying phobias and driving phobias.

Patients presenting for depression (and even anxiety) often will not even mention these phobias unless asked directly. If you do elicit a history of such phobias, you will have the opportunity to make a significant difference in a patient’s quality of life. Maybe a patient hasn’t been able to travel abroad with family, or for years has taken back roads rather than highways to get to work.

CBT can address fear of flying (though SSRIs usually don’t help). But if a patient flies only occasionally, as-needed BZDs are often the perfect solution. They provide consistent relief for most patients that will, at a minimum, allow them to travel wherever they want. For those with more severe anxiety, I use the “sledgehammer” approach: “Take as much medication as you need to reduce your anxiety. As long as you are not driving once you land, the worst that can happen is you will fall asleep during the flight.” Due to its fast-acting nature, alprazolam will usually be the best choice for flying phobias.

In studies, alprazolam has routinely been dosed up to 6 mg/day and, in panic disorder trials, 10 mg/day, so even very high doses are safe. For patients who get anticipatory anxiety, I instruct them to “get ahead of their anxiety,” much as pain patients are instructed to “get ahead of their pain.” This could mean taking alprazolam the night before a flight or on the way to the airport. If the anxiety continues, the patient should keep taking alprazolam every 20–30 minutes.

Since BZDs sedate and affect coordination, driving phobias present a more difficult dilemma.

Nevertheless, I do prescribe BZDs for driving phobias under the following conditions:

  1. The patient is engaged in CBT for the driving phobia
  2. The patient’s anxiety is so impairing that even getting on the road to do CBT driving exercises is a challenge

What about the risk of an accident? You must discuss this with your patient and document it in your notes, but the reality is that the risk of getting into an accident is probably greater if a patient has severe anxiety than if the patient is taking a BZD that helps alleviate some of that anxiety. For driving phobias, a mid-acting BZD, such as lorazepam or clonazepam, usually works best. Because the risks associated with sedation while driving are inherently greater, it is best to begin with the lowest possible doses and gradually titrate up.

Insomnia
Insomnia is not an anxiety disorder per se, but in many patients who develop acute insomnia, it soon will sound like one. A patient might tell you, “If I don’t get a good night’s sleep tonight, I’m going to be exhausted tomorrow and won’t be able to function at work. I haven’t been able to sleep well in weeks. I don’t know how much longer I can do this!” Here, it is crucial to educate patients about good sleep hygiene habits, with the main principle being to shift the focus away from how many hours of sleep they get, and to focus instead on sleep efficiency (Edinger JD et al, JAMA Psychiatry 2001;285(14):1856–1864). For example, instruct them to get out of bed when they can’t fall asleep after a period of time. Due to the potential for tolerance to develop over time and the risk of dependency, for chronic insomnia it is preferable to avoid BZDs. Trazodone, gabapentin, clonidine, and amitriptyline are good first-line options instead.

But in some cases, such as when insomnia is due to a severe, time-limited stressor, BZDs are the ideal choice. A typical example is the patient who complains of work stress from a looming deadline, leading to late-night racing thoughts and sleeplessness. With such acute distress, there is no need to mess around with other agents: Use a BZD to reduce the nighttime ruminations, and dose it aggressively until adequate sleep is obtained.

Given its quick onset of action and long-acting effects, diazepam is often the ideal choice for insomnia. BZDs generally are pretty “clean” in that they don’t cause much morning grogginess. Should grogginess occur, instruct your patient to take it earlier in the evening, decrease the dosage, or try a shorter-acting BZD. One thing to note, however, is that short-acting BZDs (such as alprazolam and lorazepam) can help patients fall asleep, but they can also induce middle-of-the-night awakenings as the medications begin to wear off. In these cases, switch to a longer-acting BZD.

TCPR Verdict: Benzodiazepines are an invaluable tool for treating anxiety and insomnia. Their abuse and dependency potential are vastly overstated. Use them judiciously, and you can provide tremendous relief for your patients.

 

Suggested Articles

  • Communicating With Patients About Gender August 5, 2020 What are the risks for depression and suicide with transgender patients and how can we…

Powered by Contextual Related Posts

Share this page!
Subscribe
Register for free content

Register For Free Articles

Register to receive free email newsletters with concise, practical advice for busy clinicians. You will also have access to select article content on the website and you will receive notifications of new books and special discount offers.




Courses and Book CME
Psychiatry Practice Boosters, Third Edition (2021)
The Medication Fact Book for Psychiatric Practice, Fifth Edition (2020)
2021 Carlat Psychiatry Report Self-Assessment Course
2020 Carlat Psychiatry Report Self-Assessment Course
The Child Medication Fact Book for Psychiatric Practice (2018)
Issue Archives

2021

  • Stopping Psych Meds Part 1 (February)
  • Mind-Gut Connection (January)

2020

  • Esketamine (January)
  • Telepsychiatry (May)
  • Mind-Gut Connection (January)
  • Practical Psychotherapy (November/December)
  • Mood and Menopause (October)
  • When to Use Lithium (September)
  • Traumatic Brain Injury (August)
  • Borderline Personality Disorder (June/July)
  • Psychopharmacology Algorithms (April)
  • Bipolar II (March)
  • Inflammation and Depression (February)

2020

  • Mood Disorders in Children and Adolescents (Oct/Nov/Dec)
  • Identity & Culture in Children and Adolescents (July/August/September)
  • Psychosis in Children and Adolescents (April/May/June)
  • ADHD in Children and Adolescents (Jan/Feb/Mar)

2020

  • Harm Reduction (January/February)
  • Substance Use in Health Professionals (March/April)
  • Alternative Treatment in Addiction (November/December)
  • Social Aspects of Addiction (September/October)
  • Opioid Use Disorder Treatment (July/August)
  • Emerging Risks for Old Medications (May/June)

2019

  • Depression (May)
  • Adult ADHD (November/December)
  • Mental Health Apps (October)
  • How to Talk about Medication (September)
  • Side Effects Part II (August)
  • Side Effects Part I (June/July)
  • Sleep (April)
  • Parenting, Pregnancy, and Prevention (March)
  • Dark and Light Therapy (February)
  • Deprescribing (January)

2018

  • Drug Metabolism (November/December)
  • Working With Transgender Patients (October)
  • Emergency Psychiatry (September)
  • Treatment-Resistant Depression (July/August)
  • Neurobiology (June)
  • Anxiety (May)
  • Neurofeedback (April)
  • Antipsychotics Update (March)
  • Working With Families (February)
  • Bipolar Disorder (January)

2017

  • PTSD (December)
  • Retirement (November)
  • Intellectual Disability (September/October)
  • Antidepressants (July/August)
  • Personality Disorders (June)
  • Dementia (May)
  • Cognitive Behavior Therapy Techniques (April)
  • Pharmacogenetics (March)
  • Treating Psychosis (February)
  • Adult ADHD (January)

2016

  • Complementary and Alternative Medicine in Psychiatry (November/December)
  • Side Effects (October)
  • Pain Management (September)
  • Medication in Pregnancy (July/August)
  • Psychoanalysis in Modern Psychiatry (June)
  • Correctional Psychiatry (May)
  • Antidepressant Roundup (April)
  • Burnout (March)
  • Private Practice (February)
  • Bipolar Disorder (January)

2015

  • Psychiatry and General Medicine (November/December)
  • Biomarkers in Psychiatry (May)
  • Telepsychiatry (October)
  • Sleep Disorders (September)
  • Interventional Psychiatry (July/August)
  • Eating Disorders (June)
  • Psychotherapy Updates (April)
  • Topics in Geriatric Psychiatry (March)
  • Antipsychotics Update (February)
  • Risk Management (January)

2014

  • Bipolar Disorder (November/December)
  • Pharmacogenetics (October)
  • Keeping up in Psychiatry (September)
  • Research in Psychiatry (July/August)
  • Marijuana (June)
  • Psychiatric Diagnosis (May)
  • Issues in Psychopharmacology (April)
  • Schizophrenia (March)
  • Women’s Psychiatry (February)
  • Ethics in Psychiatry (January)

2013

  • Military Psychiatry (December)
  • Depression (November)
  • Treatment of Dementia (October)
  • Anxiety Disorders (September)
  • Natural and Alternative Treatments in Psychiatry (July/August)
  • Autism Spectrum Disorder (June)
  • Practice Tips (May)
  • Substance Abuse (April)
  • Medicolegal Topics (March)
  • End of Life Care (February)
  • Antipsychotic Update (January)

2012

  • Screening Tools and Tips (December)
  • Medical Comorbidities (November)
  • Devices in Psychiatry (October)
  • Eating Disorders (September)
  • Bipolar Disorder (July/August)
  • Risk Management (June)
  • Antidepressant Roundup 2012 (May)
  • Gender and Sexuality (April)
  • Personality Disorders (March)
  • ADHD (February)
  • Natural Treatments in Psychiatry (January)

2011

  • Electronic Medical Records (December)
  • Insomnia (November)
  • Psychotherapy (October)
  • Alcoholism (September)
  • Anxiety Disorders (July/August)
  • Schizophrenia (June)
  • Managing Side Effects (May)
  • Antidepressant Roundup 2011 (April)
  • DSM-5 and Diagnostic Issues (March)
  • Drug-Drug Interactions (February)
  • Bipolar Disorder (January)

2010

  • Hospital Psychiatry (December)
  • Psychiatric Medication in Pregnancy (November)
  • Maintenance of Certification (October)
  • The Neuroscience of Psychotherapy (September)
  • Treatment of Depression (July/August)
  • Email and the Internet in Psychiatry (June)
  • Substance Abuse (May)
  • The Diagnosis and Treatment of Dementia (April)
  • Ethics in Psychiatry (March)
  • Natural Treatments in Psychiatry (February)
  • ADHD (January)

2009

  • Treating Schizophrenia (December)
  • Treatment for Anxiety Disorders (November)
  • The Latest on Antidepressants (October)
  • Topics in Neuropsychiatry (September)
  • The Interface of Medicine and Psychiatry (July/August)
  • Generic Medications in Psychiatry (June)
  • The Treatment of Eating Disorders (May)
  • Healthcare Policy and Psychiatry (April)
  • Antipsychotic Roundup 2009 (March)
  • Psychiatric Medication in Pregnancy and Lactation (February)
  • Transcranial Magnetic Stimulation (January)

2008

  • Treating Fibromyalgia and Pain in Psychiatry (December)
  • Issues in Child Psychiatry (November)
  • Improving Psychiatric Practice (October)
  • Treating Personality Disorders (September)
  • Bipolar Disorder (July/August)
  • Antipsychotic Roundup 2008 (June)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Neuropsychological Testing (May)
  • Psychiatric Medications: Effects and Side Effects (April)
  • Update on Substance Abuse (March)
  • Anticonvulsants in Psychiatry (February)
  • Brain Devices in Psychiatry (January)

2007

  • The Treatment of Insomnia (December)
  • Avoiding Malpractice in Psychiatry (November)
  • Update on Eating Disorders (October)
  • Complex Psychopharmacology (September)
  • Laboratory Testing in Psychiatry (August)
  • Psychotherapy in Psychiatry (July)
  • Posttraumatic Stress Disorder (June)
  • Topics in Geriatric Psychiatry 2007 (May)
  • Pregnancy and Menopause in Psychiatry (Apil)
  • Antipsychotic Roundup 2007 (March)
  • Understanding Psychiatric Research (February)
  • Antidepressant Round-up 2007 (January)

2006

  • Technology and Psychiatric Practice (December)
  • The Use of MAOIs (November)
  • Medication Treatment of Depression (January)
  • Seasonal Affective Disorder (October)
  • Treatment of ADHD (September)
  • Topics in Bipolar Disorder (August)
  • Neurotransmitters in Psychiatry (July)
  • Treating Substance Abuse (June)
  • The STAR*D Antidepressant Trial (May)
  • Natural Treatments in Psychiatry (April)
  • Medication Treatment of Anxiety (March)
  • Panic Disorder: Making Treatment Work (March)
  • Antipsychotic Roundup 2006 (February)
  • Antidepressant Roundup 2006 (January)

2005

  • Self-Help Books and Psychiatry (December)
  • Genetics and Psychiatry (November)
  • Pregnancy and Psychiatric Treatment (October)
  • Benzodiazepines and Hypnotics in Psychiatry (September)
  • Geriatric Psychiatry Update (August)
  • Chart Documentation in Psychiatry (July)
  • The Treatment of Bipolar Disorder (June)
  • Weight Loss and Smoking Cessation in Psychiatry (May)
  • Treating ADHD (April)
  • Drug Industry Influence in Psychiatry (March)
  • Atypical Antipsychotics 2005 (February)
  • Antidepressant Roundup 2005 (January)

2004

  • Sexual Dysfunction (December)
  • Suicide Prevention (November)
  • To Sleep, To Awake (October)
  • Women’s Issues in Psychiatry (September)
  • OCD: An Update (August)
  • Chronic Pain and Psychiatry (July)
  • Neuroimaging in Psychiatry (June)
  • Natural Medications in Psychiatry (May)
  • Posttraumatic Stress Disorder (April)
  • Treatment of Alcoholism (March)
  • Battle of the Atypicals (February)
  • Antidepressant Roundup, 2004 (January)

2003

  • Research Methods in Psychiatry (December)
  • Antidepressants in Children (November)
  • The Treatment of Dementia (October)
  • Bipolar Disorder, Part II: The Novel Anticonvulsants (September)
  • Bipolar Disorder: The Basics (August)
  • Drug-Drug Interactions in Psychiatry (July)
  • Managing Antidepressant Side Effects (June)
  • Antidepressants in Pregnancy and Lactation (May)
  • ADHD: Medication Options (April)
  • Panic Disorder: Making Treatment Work (March)
  • Atypical Antipsychotics in Clinical Practice (February)
  • Medication Treatment of Depression (January)

2019

  • Autism in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (May/June/July/August)
  • Substance Use in Children and Adolescents (September/October)
  • Trauma in Children and Adolescents (March/April)
  • Anxiety in Children and Adolescents (January/February)

2018

  • Psychotropic Risks in Children and Adolescents (May/June)
  • ADHD in Children and Adolescents (November/December)
  • Depression in Children and Adolescents (September/October)
  • Autism in Children and Adolescents (July/August)
  • Anxiety in Children and Adolescents (March/April)
  • Suicide in Children and Adolescents (January/February)

2017

  • Adolescents (November/December)
  • ADHD in Children and Adolescents (September/October)
  • Psychosis in Children and Adolescents (August)
  • PANDAS, PANS, and Related Disorders (June/July)
  • Marijuana in Children and Adolescents (May)
  • Tourette’s and Other Tic Disorders in Children and Adolescents (March/April)
  • Autism in Children and Adolescents (January/February)

2016

  • Gender Dysphoria in Children and Adolescents (November/December)
  • Technology Issues With Children and Adolescents (September/October)
  • Mood Dysregulation in Children and Adolescents (July/August)
  • Eating Disorders in Children and Adolescents (May/June)
  • Conduct Disorder in Children and Adolescents (April)
  • Sleep Disorders in Children and Adolescents (March)
  • ADHD in Children and Adolescents (January/February)

2015

  • Antidepressant Use in Children (November/December)
  • Foster Care and Child Psychiatry (September/October)
  • Autism (July/August)
  • Trauma (May/June)
  • Anxiety Disorders (April)
  • Schools and Psychiatry (March)
  • Emergency Psychiatry in Children (January/February)

2014

  • Antipsychotics in Children (December)
  • ADHD (November)
  • Gender and Sexuality (September/October)
  • Psychotic Symptoms (Summer)
  • Medication Side Effects (May)
  • Food and Mood (April)
  • Learning and Developmental Disabilities (February)

2013

  • Complex Practice Issues (December)
  • Diet and Nutrition (November)
  • Child Psychiatry in DSM-5 (August/September)
  • Medication Side Effects and Interactions (June/July)
  • Problematic Technology (March/April)
  • Autism Spectrum Disorders (January/February)

2012

  • Bipolar Disorder (December)
  • Substance Abuse (October/November)
  • Transitional Age Youth (July/August)
  • Rating Scales (May/June)
  • Eating Disorders (March/April)
  • Behavioral Disorders (February)

2011

  • Treatment of Anxiety Disorders (December)
  • Trauma (November)
  • Bullying and School Issues (October)
  • Hidden Medical Disorders (August)
  • OCD and Tic Disorders (June)
  • Suicide and Non-Suicidal Self Injury (April)
  • Sleep Disorders (March)
  • ADHD (January)

2010

  • Use of Antipsychotics in Children and Adolescents (December)
  • Learning and Developmental Disabilities (October)
  • Major Depression (September)
  • Treating Children and Families (July)
  • The Explosive Child (May)

2019

  • Dual Diagnosis in Addiction Medicine (May/June)
  • Medical Issues in Addiction Practice (November/December)
  • Alcohol Addiction (September/October)
  • Legal Issues in Addiction Medicine (July/August)
  • Traumatic Brain Injury and Addiction (March/April)
  • Board Certification in Addiction Medicine (January/February)

2018

  • Opioid Addiction (November/December)
  • Addiction in Older Adults (October)
  • Sleep Disorders and Addiction (September)
  • Adolescent Addiction (July/August)
  • Pain and Addiction (May/June)
  • Cannabis and Addiction (March/April)
  • Stigma and Addiction (January/February)

2017

  • Pregnancy and Addiction (November/December)
  • Detox (Sepember/October)
  • Dual Diagnosis (August)
  • Alternatives to 12-Step Programs (June/July)
  • Recovery (May)
  • Psychiatric Uses of Street Drugs (March/April)
  • Sex Addiction (January/February)

2016

  • Prescription Drug Monitoring Programs (PDMPs) (November/December)
  • Addiction in Health Care Professionals (September/October)
  • Dialectical Behavior Therapy in Addiction (August)
  • Motivational Interviewing (June/July)
  • Benzodiazepines (May)
  • Opioid Addiction (March/April)
  • Families and Substance Abuse (January/February)

2015

  • The Twelve Steps (November/December)
  • Designer Drugs (September/October)
  • Residential Treatment Programs Decoded (July/August)
  • Nicotine and E-Cigarettes (June)
  • Drug Screening (April/May)
  • Integrating Therapy and Medications for Alcoholism (March)
  • Detoxification Protocols (January/February)

2014

  • Behavioral Addictions (December)
  • Risk and Reimbursement (November)
  • Stimulant Abuse (September/October)
  • Self-Help Programs (June)
  • Opioid Addiction (May)
  • Coping with Bad Outcomes (March)
  • Change Management in Addiction Treatment (January/February)

2013

  • Cocaine Addiction (December)
  • Relapse Prevention (November)
  • Cannabis Addiction (August/September)
  • Addiction in DSM-5 (June/July)
Editor-in-Chief

Chris Aiken, MD

Dr. Aiken is the director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice.

Full Editorial Information

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Subscriptions
  • Books
  • Online Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Child Psychiatry Report

Contact

  • info@thecarlatreport.com
  • 866-348-9279
  • PO Box 626, Newburyport MA 01950

Follow Us

© 2021 Carlat Publishing, LLC and Affiliates, All Rights Reserved.

Please see our Privacy Policy and the Hardware/Software Requirements to view our website.

×